抗程序性死亡配体1免疫治疗在合并系统性硬化的癌症患者中的上市后IV期安全性评估研究
Scleronco-01是一项多中心、全国性、开放标签、IV期观察性研究,2019至2021年纳入17例合并系统性硬化(SSc)的癌症患者,接受抗PD-1或PD-L1免疫治疗。中位随访12个月,4例(24%)出现SSc症状 flare-up,10例(59%)发生免疫相关不良事件,总体缓解率41%(7/17),中位总生存期15.8个月(95%CI 7.3至未达到)。作者认为抗PD-1或PD-L1免疫治疗是合并SSc癌症患者的合适选择,需更长随访进行长期安全性分析。
要点
- 17例合并SSc的癌症患者接受抗PD-1/PD-L1治疗,中位随访12个月。
- 4例(24%)出现SSc症状 flare-up,10例(59%)发生免疫相关不良事件。
- 总体缓解率41%(7/17),中位总生存期15.8个月(95%CI 7.3至未达到)。
核心结论
- 抗PD-1或PD-L1免疫治疗是合并SSc癌症患者的合适选择。
- 需要更长随访期进行长期安全性分析。
研究设计与样本
- Scleronco-01为多中心、全国性、开放标签、IV期观察性研究,开展于2019至2021年。
- 共纳入17例合并系统性硬化(SSc)的癌症患者。
- 中位(四分位距)年龄为60(34-82)岁。
- 15例(88%)接受抗PD-1治疗(纳武利尤单抗和帕博利珠单抗),2例(12%)接受抗PD-L1治疗(度伐利尤单抗)。
- 中位随访时间为12个月(范围2-38个月)。
主要发现
- 17例患者中,肺癌13例(77%)、头颈癌2例(12%)、黑色素瘤1例(6%)、结直肠癌1例(6%)。
- 4例(24%)出现SSc症状 flare-up。
- 10例(59%)发生免疫相关不良事件,其中I-II级11例(65%)、III-IV级1例(6%),无V级。
- 总体缓解率为41%(7/17例)。
- 中位总生存期为15.8个月(95%CI 7.3至未达到)。
临床怎么用
- 作者认为抗PD-1或PD-L1免疫治疗是合并SSc癌症患者的合适选择。
- 作者指出需要更长随访期进行长期安全性分析。
局限性
- 需要更长随访期进行长期安全性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cancer patients with pre-existing autoimmune disease, such as systemic sclerosis (SSc), are excluded from clinical trials, so the data on tolerability and efficacy of immune checkpoint inhibitors in these patients are limited. This study investigated the tolerability and efficacy of anti-programmed death ligand 1 (PD (L)1) immunotherapies in patients with pre-existing SSc. METHODS: Scleronco-01 was a multicentre, nationwide, open-label, phase IV observational study, from 2019 to 2021. RESULTS: Seventeen SSc patients receiving treatment for lung carcinoma (n = 13, 77%), head and neck cancer (n = 2, 12%), melanoma (n = 1, 6%), and colorectal carcinoma (n = 1, 6%) were included. The median (interquartile range) patient age was 60 (34-82) years. Fifteen (88%) patients received anti-PD1 (nivolumab and pembrolizumab) and two (12%) anti-PD-L1 (durvalumab). The median follow-up duration was 12 (range, 2-38) months. Four patients (24%) experienced flare-up of SSc symptoms. Ten patients (59%) developed an immune-related adverse event (grade I-II in 11 patients [65%], grade III-IV in one [6%]) without grade V. The overall response rate was 41% (7/17 patients). The median overall survival was 15.8 (95% confidence interval: 7.3 to not reached) months. CONCLUSION: Anti-PD1 or PD-L1 immunotherapies are suitable options for cancer patients with pre-existing SSc. Longer follow-up periods are required for long-term safety analyses.
引用
- Panhaleux M, Espitia O, Terrier B, et al. Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study. Eur J Cancer. 2021. PMID: 34810048. doi:10.1016/j.ejca.2021.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。